"We entered 2020 with a focused agenda for leveraging our Accordion Pill platform in both the near- and long-term, with goals to outlicence our late-stage Parkinson's disease program, to advance our ...

JERUSALEM, Dec. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the Company has entered into an Ordinary Shares Purchase Agreement for $10.0 ...

JERUSALEM, Nov. 12, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three and nine months ended September 30, 2019.

TEL AVIV (Reuters) - Israel's Intec Pharma, which is conducting a late stage trial for its long-lasting pill to treat Parkinson's disease, expects to start earning money from the program sometime in ...

Shares of biotech Intec Pharma Ltd. plunged 80% in premarket trade Monday after the company said its late-stage trial of a drug meant to treat symptoms of advanced Parkinson's disease did not result ...

Jeffrey Meckler, chief executive of Israel's Intec Pharma holds up their long-lasting pill to treat Parkinson's disease, during an interview with Reuters in Tel Aviv, Israel November 7, 2018.